Medroxyprogesterone acetate-resistant endometrial cancer cells are susceptible to ferroptosis inducers.
Sign Up to like & getrecommendations! Published in 2023 at "Life sciences"
DOI: 10.2139/ssrn.4355249
Abstract: AIMS Medroxyprogesterone acetate (MPA) is the most common fertility-sparing treatment in patients with early-stage endometrial cancer. If MPA treatment fails, hysterectomy is recommended. Thus, there is an urgent need for novel treatment approaches for MPA-resistant… read more here.
Keywords: endometrial cancer; mpa resistant; ferroptosis inducers; treatment ... See more keywords